New Drug Shows Promise for Ataxia-Telangiectasia in Phase III Trial

A Phase III clinical trial for levacetylleucine in treating Ataxia-Telangiectasia has shown positive results. The study, published in The Lancet Neurology, indicated significant improvements in neurological symptoms and function. The drug was also reported to be generally well-tolerated by patients.